BPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid chain — derived from a partial sequence of a naturally-occurring protein in human gastric juice. Continuously researched since 1991, primarily out of the University of Zagreb, with a substantial animal-model literature and a small but growing human trial base.
Mechanism
The research literature centers on three overlapping mechanisms:
- Angiogenesis — promotion of new blood-vessel formation at the injury site, which speeds nutrient delivery to healing tissue.
- Fibroblast activity — upregulation of the cells responsible for producing collagen and extracellular matrix.
- Nitric oxide pathway modulation — interaction with the eNOS system, relevant to both vascular and gastrointestinal healing.
These mechanisms combine to explain the peptide's broad footprint across injury models — tendon, ligament, muscle, gut lining, cornea, and burn wound.
Common research protocols
The most commonly cited human observational protocol runs 4 to 6 weeks on, followed by 2 to 4 weeks off. Dosing figures below reflect the literature — not medical advice.
- Standard research dose: 250 mcg twice daily, subcutaneous, injected adjacent to the area of interest when possible.
- Reconstitution: 5 mg vial with 2 mL bacteriostatic water yields 2.5 mg/mL (25 mcg per U-100 unit).
- Draw: 10 units on a U-100 insulin syringe for a 250 mcg dose (0.10 mL).
- Doses per vial: 20 at 250 mcg per dose.
- Cycle: most protocols cycle 4-6 weeks on / 2-4 weeks off; long uninterrupted use has not been well-studied.
What the human data shows — and doesn't
Animal models (extensive). BPC-157 has been studied across gastric ulcer, Achilles tendon-to-bone reattachment, transected muscle, colitis, burn wound, and corneal healing models. Findings are consistent across these models: accelerated tissue recovery, increased angiogenesis at the injury site, reduced inflammatory infiltrate.
Human data (growing but limited). A handful of small-scale observational studies and a growing anecdotal record. No completed Phase 3 human trial for the general recovery indication as of publication.
What we do not know. Long-term human safety data (studies rarely exceed 12 weeks); interaction profile with common medications; pharmacokinetics of oral versus subcutaneous administration in humans.
Side-effect profile in the literature
Reported adverse effects in animal-model and small human observational studies have been mild and infrequent — typically injection-site discomfort, occasional mild flushing or fatigue on the first dose. No consistent signal for serious adverse events has been reported at commonly-studied doses.
This is not a safety guarantee. Long-term human safety data does not yet exist at scale. Buyers researching human application should coordinate with a licensed clinician.
Common stacks
BPC-157 is frequently paired with TB-500 (a fragment of thymosin beta-4) in the recovery literature. The two are typically dosed together over 4 to 6 weeks. We stock both individually and as a pre-blended vial (5 mg + 5 mg) for buyers running the combined protocol.
Primary literature (selected)
primary literature reviewed for this guide. Full list on request via contact.